Schering Points To 5 R&D "Stars," But Antithrombotic Shines Brightest
This article was originally published in Pharmaceutical Approvals Monthly
Schering-Plough's investigational thrombin receptor antagonist has the potential to be a transformative commercial opportunity for the drug maker. The product is one of five pipeline "stars" management highlighted during an R&D update Nov. 24, and one investors are keeping an especially close eye on
You may also be interested in...
Last Of The Primary Care Blockbusters? New Antithrombotics Line Up To Unseat Warfarin, Heparins, Plavix
Although the mainstays of antithrombotic therapy have remained the same for decades, a lengthy R&D assault by pharma – including some of the largest clinical trials ever conducted – has produced potential game-changers that have made it to FDA review for both major blood clot approaches: anticoagulation and platelet inhibition.
Safety concerns render anesthesia injection “not approvable” in U.S.
Schering-Plough's planned acquisition of Organon would provide Schering with the entrée into the central nervous system marketplace it has been seeking